AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20525323 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise time (ETT) and Canadian Cardiovascular Society (CCS) angina severity class
Number of subjects: 0
Study 20525323 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted EQ‐5D index values
Number of subjects: 0
Study 20525323 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapping of EQ‐5D index
Number of subjects: 0
Study 18827247 — intervention group
Group type: EXPERIMENTAL
Intervention: One cage (group 1)
Number of subjects: 100
Study 18827247 — intervention group
Group type: EXPERIMENTAL
Intervention: Two cages (group 2)
Number of subjects: 100
Study 15886860 — intervention group
Group type: EXPERIMENTAL
Intervention: Coca Cola (2.5 l per day)
Number of subjects: 11
Study 15886860 — intervention group
Group type: COMPARATOR
Intervention: Semi-skimmed milk (2.5 l per day)
Number of subjects: 11
Study 11803087 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell culture-derived vaccine
Number of subjects: 940
Study 11803087 — intervention group
Group type: COMPARATOR
Intervention: Egg-derived vaccine
Number of subjects: 940
Study 11803087 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 940
Study 10404100 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA >/= 3 ng/ml as a direct biopsy indicator
Number of subjects: 0
Study 10404100 — intervention group
Group type: COMPARATOR
Intervention: PSA < 4 ng/ml with DRE and TRUS
Number of subjects: 0
Study 10404100 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic-regression model predicting cancers for PSA < 4 ng/ml
Number of subjects: 0
Study 7587256 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 0.037 g/kg bolus followed by 0.025 g/kg/hr infusion
Number of subjects: 42
Study 7587256 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone 5 mg/kg bolus and 10 mg/kg/24-hr infusion
Number of subjects: 42
Study 7587256 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 42
Study 7587256 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 42
Study 2262840 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt
Number of subjects: 100
Study 2262840 — intervention group
Group type: COMPARATOR
Intervention: Milk
Number of subjects: 100
Study 6249047 — intervention group
Group type: EXPERIMENTAL
Intervention: Supercol (experiment B)
Number of subjects: 40
Study 6249047 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannucol (experiment C)
Number of subjects: 40
Study 6249047 — intervention group
Group type: COMPARATOR
Intervention: 100 g glucose (experiment A)
Number of subjects: 40
Study 6249047 — intervention group
Group type: COMPARATOR
Intervention: Placebo substance (experiment D)
Number of subjects: 40
Study 30358116 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2 mg + Dutasteride 0.5 mg + Imidafenacin 0.2 mg (TDI)
Number of subjects: 163
Study 30358116 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin + Dutasteride (TD)
Number of subjects: 163
Study 29352704 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose E1224 (4000 mg over 8 weeks)
Number of subjects: 231
Study 29352704 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose E1224 (2000 mg over 8 weeks)
Number of subjects: 231
Study 29352704 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-dose E1224 (2400 mg over 4 weeks + 4 weeks placebo)
Number of subjects: 231
Study 29352704 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole (5 mg/kg per day for 60 days)
Number of subjects: 231
Study 29352704 — intervention group
Group type: COMPARATOR
Intervention: Placebo (E1224-matched tablets for 8 weeks)
Number of subjects: 231
Study 26386865 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinect training three times a week for 3 weeks
Number of subjects: 13
Study 26386865 — intervention group
Group type: COMPARATOR
Intervention: Normal activities
Number of subjects: 13
Study 24411476 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheepskin mattress (SSM)
Number of subjects: 18
Study 24411476 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheepskin mattress combined with control mattress (SSM+CM)
Number of subjects: 18
Study 24411476 — intervention group
Group type: COMPARATOR
Intervention: Control mattress (CM)
Number of subjects: 18
Study 24411476 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital mattress (SHM)
Number of subjects: 18
Study 24411476 — intervention group
Group type: COMPARATOR
Intervention: Alternative mattress combined with control mattress (AM+CM)
Number of subjects: 18
Study 22301195 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (target dose of 30 mg/d)
Number of subjects: 200
Study 22301195 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 200
Study 19204566 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sprint and resistance training (SRT)
Number of subjects: 25
Study 19204566 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint training only (ST)
Number of subjects: 25
Study 19204566 — intervention group
Group type: COMPARATOR
Intervention: Resistance training only (RT)
Number of subjects: 25
Study 19204566 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 25
Study 19204566 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT and ST groups
Number of subjects: 25
Study 19204566 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT group
Number of subjects: 25
Study 19204566 — intervention group
Group type: EXPERIMENTAL
Intervention: All training groups
Number of subjects: 25
Study 17994478 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Therapeutic Community (MTC)
Number of subjects: 139
Study 17994478 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 139
Study 16389980 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-exposure DE subtraction chest radiography
Number of subjects: 100
Study 16389980 — intervention group
Group type: COMPARATOR
Intervention: Chest radiography alone
Number of subjects: 100
Study 16389980 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiography with DE subtraction images
Number of subjects: 100
Study 11733877 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetrical body-weight distribution training
Number of subjects: 54
Study 11733877 — intervention group
Group type: COMPARATOR
Intervention: Conventional stroke rehabilitation program
Number of subjects: 54
Study 9015133 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bolus dose of 5 mg Cr(VI)/L in drinking water (0.5 L swallowed in 2 min)
Number of subjects: 5
Study 9015133 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bolus dose of 10 mg Cr(VI)/L in drinking water (0.5 L swallowed in 2 min)
Number of subjects: 5
Study 9015133 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated exposure to 5 mg Cr(VI)/L in drinking water (1 L/d for 3 days, 3 doses of 0.33 L each day at 6-h intervals)
Number of subjects: 5
Study 9015133 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated exposure to 10 mg Cr(VI)/L in drinking water (1 L/d for 3 days, 3 doses of 0.33 L each day at 6-h intervals)
Number of subjects: 5
Study 9015133 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall ingestion of Cr(VI) at 5 and 10 mg Cr(VI)/L
Number of subjects: 5
Study 9015133 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of Cr(VI) on an empty stomach
Number of subjects: 5
Study 9015133 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 5
Study 9015133 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical environment in the gastrointestinal tract and blood
Number of subjects: 5
Study 8314361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 6
Study 8314361 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 6
Study 8314361 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 6
Study 8314361 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine, Ranitidine, Famotidine (combined effect)
Number of subjects: 6
Study 3662156 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading a three-page review (n = 33)
Number of subjects: 67
Study 3662156 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing a 15-minute videotape (n = 34)
Number of subjects: 67
Study 31136622 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing to predictable beats
Number of subjects: 2
Study 31136622 — intervention group
Group type: COMPARATOR
Intervention: Playing to unpredictable beats
Number of subjects: 2
Study 31136622 — intervention group
Group type: COMPARATOR
Intervention: Rhythmic patterns that were similar, predictable, or independent
Number of subjects: 2
Study 28507362 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab treatment
Number of subjects: 28
Study 28507362 — intervention group
Group type: COMPARATOR
Intervention: Control group (observation)
Number of subjects: 28
Study 26027814 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily conversational interactions using remote video telecommunications software
Number of subjects: 0
Study 26027814 — intervention group
Group type: COMPARATOR
Intervention: Normal cognitive function (control group)
Number of subjects: 0
Study 26027814 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model including average proportion of word counts spoken by subjects
Number of subjects: 0
Study 23688821 — intervention group
Group type: EXPERIMENTAL
Intervention: HF meal rich in MUFAs (42% of total energy)
Number of subjects: 15
Study 23688821 — intervention group
Group type: COMPARATOR
Intervention: HF meal rich in SFAs (45% of total energy)
Number of subjects: 15
Study 23688821 — intervention group
Group type: COMPARATOR
Intervention: HF meal rich in PUFAs (42% of total energy)
Number of subjects: 15
Study 21142584 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated occlusal appliance (R)
Number of subjects: 66
Study 21142584 — intervention group
Group type: COMPARATOR
Intervention: Stabilization appliance (S)
Number of subjects: 66
Study 19262219 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 10 cmH2O
Number of subjects: 71
Study 19262219 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 5 cmH2O
Number of subjects: 71
Study 19262219 — intervention group
Group type: COMPARATOR
Intervention: PEEP 0 cmH2O (Control Group)
Number of subjects: 71
Study 16740812 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely patient feedback in the form of a letter providing recent patient-specific symptoms, medication, and health service use combined with guideline-based recommendations for changes in therapy.
Number of subjects: 937
Study 16740812 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 937
Study 15615259 — intervention group
Group type: EXPERIMENTAL
Intervention: LSG9 (VEPA-B/FEPP-AB/M-FEPA, treated 3 times every 10 weeks for 28 weeks total)
Number of subjects: 447
Study 15615259 — intervention group
Group type: COMPARATOR
Intervention: mLSG4 (VEPA-B/FEPP-B/M-FEPA, treated 4 times every 14 weeks for 54 weeks total)
Number of subjects: 447
Study 15615259 — intervention group
Group type: EXPERIMENTAL
Intervention: LSG9
Number of subjects: 447
Study 15615259 — intervention group
Group type: COMPARATOR
Intervention: mLSG4
Number of subjects: 447
Study 11731187 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg E(2)V + 2.5 mg MPA
Number of subjects: 440
Study 11731187 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg E(2)V + 5 mg MPA
Number of subjects: 440
Study 11731187 — intervention group
Group type: COMPARATOR
Intervention: 2 mg E(2) + 1 mg NETA
Number of subjects: 440
Study 11731187 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2)V/MPA (increased to 2 mg after 6 months)
Number of subjects: 440
Study 11731187 — intervention group
Group type: EXPERIMENTAL
Intervention: All dose combinations
Number of subjects: 440
Study 11731187 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 440
Study 11731187 — intervention group
Group type: COMPARATOR
Intervention: E(2)/NETA
Number of subjects: 440
Study 11731187 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2)V/MPA
Number of subjects: 440
Study 8607227 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (1 mg daily for 3 days, then 2 mg daily for 25 days, titrated to 5 or 10 mg if needed)
Number of subjects: 2084
Study 8607227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2084
Study 8607227 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 2084
Study 1544220 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon‐alpha 2b (IFN‐alpha 2b) treatment, 3 x 10(6) U three times weekly for 36 weeks
Number of subjects: 33
Study 1544220 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon‐alpha 2b (IFN‐alpha 2b) treatment
Number of subjects: 33
Study 1544220 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with IFN‐alpha 2b)
Number of subjects: 33
Study 3907893 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 10
Study 3907893 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 10
Study 3907893 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 10
Study 3907893 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-line therapy (general)
Number of subjects: 10
Study 30277500 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiannual influenza vaccination (IIV3)
Number of subjects: 200
Study 30277500 — intervention group
Group type: COMPARATOR
Intervention: Control group (tetanus-diphtheria-pertussis vaccination)
Number of subjects: 200
Study 30468238 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch (16 g of resistant starch Hi‐Maize® 260)
Number of subjects: 31
Study 30468238 — intervention group
Group type: COMPARATOR
Intervention: Placebo (manioc flour)
Number of subjects: 31
Study 26724745 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (200,000 IU at first, followed by 25,000 IU every 2 weeks)
Number of subjects: 158
Study 26724745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 24795475 — intervention group
Group type: EXPERIMENTAL
Intervention: Single vaccine dose of unadjuvanted split‐virus H1N1 A/California/07/2009 influenza vaccine
Number of subjects: 0
Study 24795475 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of unadjuvanted split‐virus H1N1 A/California/07/2009 influenza vaccine
Number of subjects: 0
Study 22613104 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound prescription (radix astragali + codonopsis pilosula + tortoise plastron)
Number of subjects: 57
Study 22613104 — intervention group
Group type: EXPERIMENTAL
Intervention: Radix astragali
Number of subjects: 57
Study 22613104 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 57
Study 20830787 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN alfa‐2b with or without lamivudine for 52 weeks
Number of subjects: 221
Study 20830787 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (PEG‐IFN with lamivudine)
Number of subjects: 221
Study 20830787 — intervention group
Group type: COMPARATOR
Intervention: No decline at week 12
Number of subjects: 221
Study 18855259 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride 2.5-5 mg/day
Number of subjects: 82
Study 18855259 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10-20 mg/day
Number of subjects: 82
Study 15700156 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical personnel's evaluation of therapy goals
Number of subjects: 133
Study 15700156 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical personnel's evaluation of psychological distress and social improvements
Number of subjects: 133
Study 15700156 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical personnel's evaluation of therapeutic expenditure
Number of subjects: 133
Study 12441218 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein (a) serum levels (Lp(a))
Number of subjects: 118
Study 10355867 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine intake (3.8 g/d) during diet B
Number of subjects: 8
Study 10355867 — intervention group
Group type: COMPARATOR
Intervention: Nitrate/nitrite-free diet with no L-arginine intake during diet A
Number of subjects: 8
Study 10355867 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets (A and B)
Number of subjects: 8
Study 7867553 — intervention group
Group type: EXPERIMENTAL
Intervention: SIDS siblings
Number of subjects: 50
Study 7867553 — intervention group
Group type: COMPARATOR
Intervention: Control infants
Number of subjects: 50
Study 1441705 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneously applied collagen (group A; n = 50)
Number of subjects: 100
Study 1441705 — intervention group
Group type: COMPARATOR
Intervention: Conventional pressure dressing (group B; n = 50)
Number of subjects: 100
Study 3936086 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (whisky) consumed by experimental subjects, producing approximately 0.08% blood alcohol concentration.
Number of subjects: 60
Study 3936086 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alcohol consumption).
Number of subjects: 60
Study 29854372 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulforaphane (derived from broccoli sprouts and seeds), 12-week open-label study
Number of subjects: 15
Study 29045941 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine-based regimen
Number of subjects: 38133
Study 29045941 — intervention group
Group type: COMPARATOR
Intervention: Other antihypertensives
Number of subjects: 38133
Study 29045941 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline eGFR
Number of subjects: 38133
Study 29045941 — intervention group
Group type: EXPERIMENTAL
Intervention: High SBP, age, male gender, smoking
Number of subjects: 38133
Study 23721750 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g/l carbohydrate, 20 g/l milk protein solution (CP20)
Number of subjects: 8
Study 23721750 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g/l carbohydrate, 40 g/l milk protein solution (CP40)
Number of subjects: 8
Study 23721750 — intervention group
Group type: COMPARATOR
Intervention: 60 g/l carbohydrate solution (C)
Number of subjects: 8
Study 20640974 — intervention group
Group type: EXPERIMENTAL
Intervention: African-American women
Number of subjects: 494
Study 20640974 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic women
Number of subjects: 494
Study 20640974 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian women
Number of subjects: 494
Study 20640974 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall pregnant women
Number of subjects: 494
Study 19082847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraporous beta‐tricalcium phosphate (beta‐TCP)
Number of subjects: 40
Study 19082847 — intervention group
Group type: COMPARATOR
Intervention: Autogenous iliac crest bone graft (ICBG)
Number of subjects: 40
Study 17926619 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture between 7:00-11:00 a.m.
Number of subjects: 120
Study 17926619 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at any time (control group)
Number of subjects: 120
Study 15569122 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 800 IU b.d.
Number of subjects: 51
Study 15569122 — intervention group
Group type: COMPARATOR
Intervention: Control (alpha-interferon/ribavirin therapy)
Number of subjects: 51
Study 11512648 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting Group (intrathecal anaesthesia in sitting position)
Number of subjects: 90
Study 11512648 — intervention group
Group type: COMPARATOR
Intervention: Lateral Group (intrathecal anaesthesia in lateral position)
Number of subjects: 90
Study 11512648 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 9283675 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent polyurethane dressings
Number of subjects: 229
Study 9283675 — intervention group
Group type: COMPARATOR
Intervention: Gauze dressings
Number of subjects: 229
Study 8396086 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg od for 3 days)
Number of subjects: 99
Study 8396086 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav (625 mg tid for 10 days)
Number of subjects: 99
Study 3094657 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 units of anisoylated plasminogen streptokinase activator complex (APSAC)
Number of subjects: 149
Study 3094657 — intervention group
Group type: COMPARATOR
Intervention: Control group (no APSAC)
Number of subjects: 149
Study 3094657 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 149
Study 3094657 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 149
Study 30558680 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term cefazolin
Number of subjects: 0
Study 30558680 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term cefazolin
Number of subjects: 0
Study 30558680 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term cefazolin + vancomycin
Number of subjects: 0
Study 30558680 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term cefazolin + vancomycin
Number of subjects: 0
Study 26436865 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Immunotherapy (SCIT)
Number of subjects: 0
Study 26436865 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual Immunotherapy (SLIT)
Number of subjects: 0
Study 26436865 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 0
Study 23184062 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive videogame distraction with VR helmet
Number of subjects: 62
Study 23184062 — intervention group
Group type: COMPARATOR
Intervention: Interactive videogame distraction without VR helmet
Number of subjects: 62
Study 21852334 — intervention group
Group type: EXPERIMENTAL
Intervention: Home monitoring (HM) with daily spirometry and medical feedback
Number of subjects: 50
Study 21852334 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CT)
Number of subjects: 50
Study 21852334 — intervention group
Group type: EXPERIMENTAL
Intervention: Home monitoring (HM)
Number of subjects: 50
Study 20544649 — intervention group
Group type: EXPERIMENTAL
Intervention: OGU model (acute orthogeriatric unit)
Number of subjects: 224
Study 20544649 — intervention group
Group type: COMPARATOR
Intervention: CG model (usual model of care)
Number of subjects: 224